Hypertrichosis

Summary

Hypertrichosis (MONDO:0019280) is a disease (an umbrella term covering 11 Mondo subtypes) caused by FGF5 (GenCC Strong), with 7 cohort genes and 11 clinical trials. Top therapeutic interventions include bimatoprost.

At a glance

• Causal gene: FGF5 (GenCC Strong)
• Umbrella term: 11 Mondo subtypes
• Cohort genes: 7
• ClinVar variants: 9
• Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hypertrichosis
Mondo ID	MONDO:0019280
MeSH	D006983
Orphanet	79365
DOID	DOID:420
ICD-11	2042627850
SNOMED CT	29966009
UMLS	C0020555
MedGen	43787
MedDRA	10020864
Is cancer (heuristic)	no

Also known as: hypertrichosis · hypertrichosis (disease)

Data availability: 9 ClinVar variants · 1 GenCC gene-disease record · 1 HPO phenotype.

Disease family

An umbrella term covering 11 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › disorder of pilosebaceous unit › hypertrichosis

Related subtypes (8): piedra, hypotrichosis, hair follicle neoplasm, folliculitis, sebaceous gland disorder, hair anomaly, Katsantoni-Papadakou-Lagoyanni syndrome, trichostasis spinulosa

Subtypes (11): hypertrichosis of eyelid, gingival fibromatosis-hypertrichosis syndrome, hypertrichosis cubiti-short stature syndrome, cataract-hypertrichosis-intellectual disability syndrome, cervical hypertrichosis-peripheral neuropathy syndrome, Rabson-Mendenhall syndrome, isolated anterior cervical hypertrichosis, acquired hypertrichosis lanuginosa, hypertrichosis lanuginosa congenita, autosomal dominant preaxial polydactyly-upperback hypertrichosis syndrome, hypertrichosis-acromegaloid facial appearance syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

9 retrieved; paginated sample, class counts are floors:

5 pathogenic, 2 likely pathogenic, 1 pathogenic/likely pathogenic, 1 uncertain significance

ClinVar	Variant (HGVS)	Gene	Classification	Review
374179	NM_001374828.1(ARID1B):c.1861C>T (p.Gln621Ter)	ARID1B	Pathogenic	criteria provided, multiple submitters, no conflicts
30986	NM_015338.6(ASXL1):c.1210C>T (p.Arg404Ter)	ASXL1	Pathogenic	criteria provided, multiple submitters, no conflicts
1047867	GRCh37/hg19 16p13.3(chr16:3784414-3821324)	CREBBP	Pathogenic	criteria provided, single submitter
1564	NM_000263.4(NAGLU):c.507_516del (p.Ser169fs)	NAGLU	Pathogenic	criteria provided, multiple submitters, no conflicts
371634	NM_000263.4(NAGLU):c.419A>G (p.Tyr140Cys)	NAGLU	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
996741	NM_012233.3(RAB3GAP1):c.151-5T>G	RAB3GAP1	Pathogenic	no assertion criteria provided
374133	NM_001374828.1(ARID1B):c.3814del (p.Leu1272fs)	ARID1B	Likely pathogenic	criteria provided, single submitter
373928	NM_000525.4(KCNJ11):c.185C>G (p.Thr62Arg)	KCNJ11	Likely pathogenic	no assertion criteria provided
523303	GRCh37/hg19 6q25.3(chr6:156772218-157870875)x3	ARID1B	Uncertain significance	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 3 · Orphanet: 24 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
FGF5	Strong	Autosomal recessive	hypertrichosis	3

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
FGF5	Orphanet:411788	Familial isolated trichomegaly
RAB3GAP1	Orphanet:1387	Cataract-intellectual disability-hypogonadism syndrome
RAB3GAP1	Orphanet:2510	Micro syndrome
ARID1B	Orphanet:1465	Coffin-Siris syndrome
ARID1B	Orphanet:251056	6q25.2q25.3 microdeletion syndrome
ASXL1	Orphanet:86845	Acute myeloid leukaemia with myelodysplasia-related features
ASXL1	Orphanet:97297	Bohring-Opitz syndrome
ASXL1	Orphanet:98823	Chronic myelomonocytic leukemia
ASXL1	Orphanet:98849	Systemic mastocytosis with associated hematologic neoplasm
ASXL1	Orphanet:98850	Aggressive systemic mastocytosis
CREBBP	Orphanet:353277	Rubinstein-Taybi syndrome due to CREBBP mutations
CREBBP	Orphanet:353281	Rubinstein-Taybi syndrome due to 16p13.3 microdeletion
CREBBP	Orphanet:370026	Acute myeloid leukemia with t(8;16)(p11;p13) translocation
CREBBP	Orphanet:592574	Menke-Hennekam syndrome
KCNJ11	Orphanet:276580	Autosomal dominant hyperinsulinism due to Kir6.2 deficiency
KCNJ11	Orphanet:276603	Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency
KCNJ11	Orphanet:552	MODY
KCNJ11	Orphanet:79134	DEND syndrome
KCNJ11	Orphanet:79644	Autosomal recessive hyperinsulinism due to Kir6.2 deficiency
KCNJ11	Orphanet:99885	Isolated permanent neonatal diabetes mellitus
KCNJ11	Orphanet:99886	Transient neonatal diabetes mellitus
KCNJ11	Orphanet:99989	Intermediate DEND syndrome
NAGLU	Orphanet:447964	Autosomal dominant Charcot-Marie-Tooth disease type 2V
NAGLU	Orphanet:79270	Sanfilippo syndrome type B

Cohort genes → proteins

7 cohort genes, 7 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	7

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
FGF5	HGNC:3683	ENSG00000138675	P12034	Fibroblast growth factor 5	gencc
RAB3GAP1	HGNC:17063	ENSG00000115839	Q15042	Rab3 GTPase-activating protein catalytic subunit	clinvar
ARID1B	HGNC:18040	ENSG00000049618	Q8NFD5	AT-rich interactive domain-containing protein 1B	clinvar
ASXL1	HGNC:18318	ENSG00000171456	Q8IXJ9	Polycomb group protein ASXL1	clinvar
CREBBP	HGNC:2348	ENSG00000005339	Q92793	CREB-binding protein	clinvar
KCNJ11	HGNC:6257	ENSG00000187486	Q14654	ATP-sensitive inward rectifier potassium channel 11	clinvar
NAGLU	HGNC:7632	ENSG00000108784	P54802	Alpha-N-acetylglucosaminidase	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
FGF5	Fibroblast growth factor 5	Plays an important role in the regulation of cell proliferation and cell differentiation.
RAB3GAP1	Rab3 GTPase-activating protein catalytic subunit	Catalytic subunit of the Rab3 GTPase-activating (Rab3GAP) complex composed of RAB3GAP1 and RAB3GAP2, which accelerates the otherwise slow GTP hydrolysis catalyzed by Rab proteins.
ARID1B	AT-rich interactive domain-containing protein 1B	Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology).
ASXL1	Polycomb group protein ASXL1	Probable Polycomb group (PcG) protein involved in transcriptional regulation mediated by ligand-bound nuclear hormone receptors, such as retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor gamma (PPARG).
CREBBP	CREB-binding protein	Acetylates histones, giving a specific tag for transcriptional activation.
KCNJ11	ATP-sensitive inward rectifier potassium channel 11	Inward rectifier potassium channel that forms the pore of ATP-sensitive potassium channels (KATP), regulating potassium permeability as a function of cytoplasmic ATP and ADP concentrations in many different cells.
NAGLU	Alpha-N-acetylglucosaminidase	Involved in the degradation of heparan sulfate.

Protein-family classification

Druggable: 2 · Difficult: 1 · Unknown: 4 · Druggable fraction: 0.29

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Ion channel	1	15.9×	0.244
Enzyme (other)	1	1.7×	0.626
Transcription factor	1	1.2×	0.626
Other/Unknown	4	1.0×	0.626

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
FGF5	Other/Unknown	no		Fibroblast_GF_fam, IL1/FGF
RAB3GAP1	Other/Unknown	no		Rab3GAP1_conserved, Rab3GAP1_C, Rab3GAP1
ARID1B	Other/Unknown	no		ARID_dom, BAF250/Osa, BAF250_C
ASXL1	Other/Unknown	no		Asxl_HARE-HTH, ASX/ASX-like, ASX-like_PHD
CREBBP	Transcription factor	no	2.3.1.48	Znf_TAZ, Znf_ZZ, Bromodomain
KCNJ11	Ion channel	yes		K_chnl_inward-rec_Kir6.2, K_chnl_inward-rec_Kir_cyto, Ig_E-set
NAGLU	Enzyme (other)	yes	3.2.1.50	NAGLU, GH_hydrolase_sf, NAGLU_N

Expression context

Cohort genes with no expression data: 0.

6 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	7
unknown	0

Top tissues across cohort

Tissue	Cohort genes
sural nerve	3
stromal cell of endometrium	2
buccal mucosa cell	1
male germ line stem cell (sensu Vertebrata) in testis	1
Brodmann (1909) area 23	1
hair follicle	1
secondary oocyte	1
bone marrow cell	1
colonic epithelium	1
adrenal tissue	1
sperm	1
amniotic fluid	1
tibia	1
gastrocnemius	1
hindlimb stylopod muscle	1
muscle of leg	1
body of pancreas	1
mucosa of stomach	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
FGF5	102	broad	marker	buccal mucosa cell, stromal cell of endometrium, male germ line stem cell (sensu Vertebrata) in testis
RAB3GAP1	300	ubiquitous	marker	hair follicle, Brodmann (1909) area 23, secondary oocyte
ARID1B	256	ubiquitous	marker	bone marrow cell, colonic epithelium, sural nerve
ASXL1	294	ubiquitous	marker	sural nerve, sperm, adrenal tissue
CREBBP	297	ubiquitous	marker	sural nerve, tibia, amniotic fluid
KCNJ11	161	broad	yes	gastrocnemius, hindlimb stylopod muscle, muscle of leg
NAGLU	268	ubiquitous	marker	stromal cell of endometrium, body of pancreas, mucosa of stomach

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
CREBBP	6,959
FGF5	3,791
ASXL1	2,816
ARID1B	2,131
RAB3GAP1	2,039
KCNJ11	1,715
NAGLU	1,200

Structural data

PDB: 6 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
CREBBP	Q92793	144
KCNJ11	Q14654	9
ASXL1	Q8IXJ9	4
ARID1B	Q8NFD5	2
RAB3GAP1	Q15042	1
NAGLU	P54802	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
FGF5	P12034	76.62

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 191. Enrichment computed across 7 evidence-associated genes (7 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
MPS IIIB - Sanfilippo syndrome B	1	1631.4×	0.039	NAGLU
Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome	1	815.7×	0.039	KCNJ11
Defective ABCC8 can cause hypo- and hyper-glycemias	1	815.7×	0.039	KCNJ11
ATP sensitive Potassium channels	1	407.9×	0.039	KCNJ11
LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production	1	326.3×	0.039	CREBBP
NFE2L2 regulating inflammation associated genes	1	326.3×	0.039	CREBBP
NFE2L2 regulating ER-stress associated genes	1	326.3×	0.039	CREBBP
Mucopolysaccharidoses	1	271.9×	0.039	NAGLU
RUNX1 regulates transcription of genes involved in differentiation of myeloid cells	1	203.9×	0.039	CREBBP
NFE2L2 regulates pentose phosphate pathway genes	1	203.9×	0.039	CREBBP
NFE2L2 regulating MDR associated enzymes	1	203.9×	0.039	CREBBP
Regulation of NFE2L2 gene expression	1	203.9×	0.039	CREBBP
Regulation of FOXO transcriptional activity by acetylation	1	163.1×	0.039	CREBBP
Regulation of gene expression by Hypoxia-inducible Factor	1	135.9×	0.039	CREBBP
Signaling by activated point mutants of FGFR1	1	135.9×	0.039	FGF5
Signaling by activated point mutants of FGFR3	1	135.9×	0.039	FGF5
Activation of the TFAP2 (AP-2) family of transcription factors	1	135.9×	0.039	CREBBP
NFE2L2 regulating tumorigenic genes	1	135.9×	0.039	CREBBP
Cellular response to hypoxia	1	125.5×	0.039	CREBBP
FGFR3c ligand binding and activation	1	125.5×	0.039	FGF5
FGFR2c ligand binding and activation	1	125.5×	0.039	FGF5
Phospholipase C-mediated cascade; FGFR3	1	125.5×	0.039	FGF5
FGFRL1 modulation of FGFR1 signaling	1	125.5×	0.039	FGF5
Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters	1	125.5×	0.039	CREBBP
Diseases of carbohydrate metabolism	1	116.5×	0.039	NAGLU
RUNX3 regulates NOTCH signaling	1	116.5×	0.039	CREBBP
FGFR1c ligand binding and activation	1	108.8×	0.039	FGF5
TRAF3-dependent IRF activation pathway	1	108.8×	0.039	CREBBP
Inwardly rectifying K+ channels	1	102.0×	0.039	KCNJ11
R-HSA-1368082	1	102.0×	0.039	CREBBP

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
cellular response to nutrient levels	2	133.8×	0.008	CREBBP, KCNJ11
determination of adult lifespan	2	123.5×	0.008	KCNJ11, NAGLU
response to disaccharide	1	2407.4×	0.014	NAGLU
regulation of kidney size	1	1203.7×	0.014	ASXL1
positive regulation of glutamate neurotransmitter secretion in response to membrane depolarization	1	1203.7×	0.014	RAB3GAP1
regulation of calcium ion-dependent exocytosis of neurotransmitter	1	1203.7×	0.014	RAB3GAP1
rod bipolar cell differentiation	1	1203.7×	0.014	NAGLU
nervous system development	3	19.7×	0.014	ARID1B, FGF5, NAGLU
N-terminal peptidyl-lysine acetylation	1	802.5×	0.015	CREBBP
establishment of protein localization to endoplasmic reticulum membrane	1	802.5×	0.015	RAB3GAP1
ganglioside metabolic process	1	601.9×	0.015	NAGLU
left ventricular cardiac muscle tissue morphogenesis	1	601.9×	0.015	NAGLU
positive regulation of protein lipidation	1	601.9×	0.015	RAB3GAP1
positive regulation of endoplasmic reticulum tubular network organization	1	601.9×	0.015	RAB3GAP1
cone retinal bipolar cell differentiation	1	601.9×	0.015	NAGLU
positive regulation of retinoic acid receptor signaling pathway	1	481.5×	0.016	ASXL1
response to resveratrol	1	481.5×	0.016	KCNJ11
cytoplasm organization	1	401.2×	0.016	NAGLU
heparin proteoglycan metabolic process	1	401.2×	0.016	NAGLU
negative regulation of peroxisome proliferator activated receptor signaling pathway	1	401.2×	0.016	ASXL1
CAMKK-AMPK signaling cascade	1	401.2×	0.016	KCNJ11
response to hypoxia	2	27.4×	0.016	CREBBP, KCNJ11
negative regulation of transcription by RNA polymerase I	1	343.9×	0.016	CREBBP
glycosaminoglycan metabolic process	1	343.9×	0.016	NAGLU
inner ear receptor cell development	1	343.9×	0.016	NAGLU
ventricular cardiac muscle tissue development	1	300.9×	0.017	KCNJ11
lung saccule development	1	300.9×	0.017	ASXL1
heparan sulfate proteoglycan catabolic process	1	267.5×	0.018	NAGLU
mitral valve morphogenesis	1	240.7×	0.018	NAGLU
homeostatic process	1	240.7×	0.018	CREBBP

Therapeutics

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 5

Druggability breadth: 3 of 7 evidence-associated genes (43%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
CREBBP	COLCHICINE
KCNJ11	PINACIDIL ANHYDROUS

Top cohort targets by molecule count

Symbol	Molecules	Max phase
CREBBP	13	4
KCNJ11	7	4
FGF5	0	0
RAB3GAP1	0	0
ARID1B	0	0
ASXL1	0	0
NAGLU	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
COLCHICINE	4	CREBBP
ALTRETAMINE	4	CREBBP
PINACIDIL ANHYDROUS	4	KCNJ11
GLYBURIDE	4	KCNJ11
PROPAFENONE	4	KCNJ11
DIAZOXIDE	4	KCNJ11
CURCUMIN	3	CREBBP
PAPAVERINE	3	CREBBP
EPIGALOCATECHIN GALLATE	3	CREBBP
MOLIBRESIB	2	CREBBP
FISETIN	2	CREBBP
ETAZOLATE	2	CREBBP
LUNRESERTIB	2	CREBBP
TRACAZOLATE	2	CREBBP
NOCODAZOLE	2	CREBBP
CROMAKALIM	2	KCNJ11
CLAMIKALANT	2	KCNJ11
TIFENAZOXIDE	2	KCNJ11
INOBRODIB	1	CREBBP
AZD-5153	1	CREBBP

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
CREBBP	687	Binding:644, Functional:43
KCNJ11	102	Functional:59, Binding:43
NAGLU	4	Binding:4

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
CREBBP	2.3.1.48	histone acetyltransferase
NAGLU	3.2.1.50	alpha-N-acetylglucosaminidase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
CREBBP	687
KCNJ11	102

Pharmacogenomics

Cohort genes with a PharmGKB record: 7; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

20 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
COLCHICINE	4	CREBBP
ALTRETAMINE	4	CREBBP
PINACIDIL ANHYDROUS	4	KCNJ11
GLYBURIDE	4	KCNJ11
PROPAFENONE	4	KCNJ11
DIAZOXIDE	4	KCNJ11
CURCUMIN	3	CREBBP
PAPAVERINE	3	CREBBP
EPIGALOCATECHIN GALLATE	3	CREBBP
MOLIBRESIB	2	CREBBP
FISETIN	2	CREBBP
ETAZOLATE	2	CREBBP
LUNRESERTIB	2	CREBBP
TRACAZOLATE	2	CREBBP
NOCODAZOLE	2	CREBBP
CROMAKALIM	2	KCNJ11
CLAMIKALANT	2	KCNJ11
TIFENAZOXIDE	2	KCNJ11
INOBRODIB	1	CREBBP
AZD-5153	1	CREBBP

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	CREBBP, KCNJ11
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	1	NAGLU
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	4	FGF5, RAB3GAP1, ARID1B, ASXL1

Undrugged target profiles

5 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
FGF5	0	—
RAB3GAP1	0	—
ARID1B	0	—
ASXL1	0	—
NAGLU	4	—

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE1/PHASE2	2
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01212172	PHASE3	COMPLETED	Comparison of Efficacy, Safety and Tolerability of Two Different 810 nm Diode Lasers for Hair Reduction
NCT00371930	PHASE1/PHASE2	UNKNOWN	Photodynamic Therapy for Permanent Hair Removal
NCT02793557	PHASE1/PHASE2	COMPLETED	Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth
NCT00580736	PHASE1	COMPLETED	Optical Clearing of the Skin in Conjunction With Laser Treatments
NCT05775328	Not specified	RECRUITING	Treatment of Hypertrichosis With Intense Pulsed Light
NCT00441948	Not specified	UNKNOWN	Enhanced Safety Laser Hair Removal System
NCT00495443	Not specified	UNKNOWN	Enhanced Safety Aesthetic Laser System
NCT00773136	Not specified	COMPLETED	Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes
NCT01912950	Not specified	COMPLETED	Pilot Study of a Novel IPL for Removal of Unwanted Fine Body Hair
NCT02536092	Not specified	WITHDRAWN	A Prospective Multi-Center Study of a Novel Dual-Wavelength Laser for Hair Removal
NCT03273504	Not specified	COMPLETED	Efficacy Evaluation of the Activity of a Cosmetic Product (Topical Use) on Hair Regrowth vs Placebo

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BIMATOPROST	4	1
CHEMBL4303730	0	1